- Home
- TIC vs WVE Comparison
TIC vs WVE Comparison
Compare TIC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIC
- WVE
- Stock Information
- Founded
- TIC 1991
- WVE 2012
- Country
- TIC United States
- WVE Singapore
- Employees
- TIC N/A
- WVE N/A
- Industry
- TIC
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- TIC
- WVE Health Care
- Exchange
- TIC Nasdaq
- WVE Nasdaq
- Market Cap
- TIC 1.5B
- WVE 1.7B
- IPO Year
- TIC N/A
- WVE 2015
- Fundamental
- Price
- TIC $9.70
- WVE $5.92
- Analyst Decision
- TIC Hold
- WVE Strong Buy
- Analyst Count
- TIC 1
- WVE 11
- Target Price
- TIC $13.00
- WVE $22.00
- AVG Volume (30 Days)
- TIC 256.8K
- WVE 1.7M
- Earning Date
- TIC 05-27-2025
- WVE 05-08-2025
- Dividend Yield
- TIC N/A
- WVE N/A
- EPS Growth
- TIC N/A
- WVE N/A
- EPS
- TIC N/A
- WVE N/A
- Revenue
- TIC $1,097,393,000.00
- WVE $108,302,000.00
- Revenue This Year
- TIC N/A
- WVE N/A
- Revenue Next Year
- TIC N/A
- WVE N/A
- P/E Ratio
- TIC N/A
- WVE N/A
- Revenue Growth
- TIC 4.51
- WVE N/A
- 52 Week Low
- TIC $2.39
- WVE $4.25
- 52 Week High
- TIC $2.60
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- TIC N/A
- WVE 33.76
- Support Level
- TIC N/A
- WVE $5.28
- Resistance Level
- TIC N/A
- WVE $6.41
- Average True Range (ATR)
- TIC 0.00
- WVE 0.62
- MACD
- TIC 0.00
- WVE -0.00
- Stochastic Oscillator
- TIC 0.00
- WVE 20.51
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.